Results 141 to 150 of about 39,319 (333)

Go for Gold: Development of a Scalable Synthesis of [1‐(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors

ChemistryOpen, EarlyView.
[1‐(Ethoxycarbonyl)cyclopropyl] triphenylphosphonium tetrafluoroborate is a limiting key reagent for synthesis of the tricyclic 5,6‐dihydropyrimido[5,4‐e]indolizine and related scaffolds, which are central to First‐in‐Class covalent inhibitors of the protein kinase monopolar spindle 1/threonine tyrosine kinase (TTK).
Leon Rebhan, Rebekka Fürst, Dieter Schollmeyer, Ricardo A. M. Serafim, Matthias Gehringer   +4 more
wiley   +1 more source

Ibrutinib and fungus: an invasive concern [PDF]

Blood, 2018
In this issue of Blood, Ghez et al report on 33 patients who developed invasive fungal infections during ibrutinib treatment, the majority of which were invasive aspergillosis, which supports the observation that fungal infections are a potential risk with ibrutinib ...
openaire   +3 more sources

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

Molecular Medicine, 2019
Background Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function.
Alexander P. de Porto, Zhe Liu, Regina de Beer, Sandrine Florquin, Onno J. de Boer, Rudi W. Hendriks, Tom van der Poll, Alex F. de Vos   +7 more
doaj   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

The Journal of Pathology, EarlyView.
Abstract In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments.
Tamás László, László Imre Pinczés, Bence Bátai, Luca Varga, Botond Timár, Anita Gulyás, Ilona Tárkányi, Márk Plander, Zsolt Nagy, Péter Rajnics, Miklós Egyed, Zsuzsa Molnár, János Rottek, András Masszi, Péter Tamáska, Róbert Szász, Árpád Illés, Donát Alpár, Ferenc Magyari, Csaba Bödör   +19 more
wiley   +1 more source

Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Patients with ataxia–telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B‐cell lymphoma ...
Samanta Catueno, Ramya Ramakrishnan, Sarah Elitzur, Miriam B. Garcia, David McCall, Cesar Nunez, Michael Roth, Alessandra Ferrajoli, Branko Cuglievan, Amber Gibson   +9 more
wiley   +1 more source

Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin

Cancer Innovation
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use.
Pengsha Li, Daiqi Liu, Pan Gao, Ming Yuan, Zhiqiang Zhao, Yue Zhang, Zandong Zhou, Qingling Zhang, Meng Yuan, Xing Liu, Gary Tse, Guangping Li, Qiankun Bao, Tong Liu   +13 more
doaj   +1 more source

Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy

Case Reports in Hematology, 2020
Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage.
Jennifer L. Miatech, John H. Hughes, Dillon K. McCarty, M. Patrick Stagg   +3 more
doaj   +1 more source

Real-world experience of Ibrutinib therapy in relapsed chronic lymphocytic leukaemia: results of a single-centre retrospective analysis [PDF]

, 2019
Background: Ibrutinib is a Bruton’s tyrosine-kinase (BTK) inhibitor that is approved as a second-line treatment in chronic lymphocytic leukemia (CLL). While recent trials have demonstrated impressive results for ibrutinib, there remains a paucity of real-
Chevassut, Timothy, Johnston, Rosalynd, Nuttall, Elisabeth, Trounce, Ellie, Tung, Joanna   +4 more
core   +1 more source

Micro‐ and nanomotors in biomedical applications

Responsive Materials, EarlyView.
Micro‐ and nanomotors (MNMs), as autonomous devices converting chemical or external energy into mechanical propulsion, have emerged as transformative drug delivery platforms in biomedicine. This review systematically outlines the design principles governing MNMs' propulsion and operation, highlights the applications of MNMs in disease treatment, and ...
Xiangyu Meng, Yuqi Tang, Quan Li
wiley   +1 more source